Titleist Capital’s Immunome IMNM Stock Holding History

Titleist Capital’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,000	Closed	-$32K	–	240
2022 Q2	$32K	Buy	+10,000	New	+$36.4K	0.01%	236

Other funds holding IMNM

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

Titleist Capital's IMNM Position: Q3 2022 in Review

Titleist Capital sold out of Immunome (IMNM) in Q3 2022, closing a stake of 10,000 shares — an estimated $32K sold.

Titleist Capital first reported a position in IMNM in Q2 2022 and held it in 1 quarter. The position peaked at $32K in Q2 2022. 24 funds tracked by Wall St. Rank hold IMNM as of Q3 2022.

Titleist Capital reported no remaining Immunome position as of Q3 2022 after selling out during the quarter.
Titleist Capital sold 10,000 Immunome shares in Q3 2022, an estimated $32K.
Titleist Capital first reported a position in Immunome in Q2 2022 and held it in 1 quarter.
Titleist Capital's Immunome position peaked at $32K in Q2 2022.
24 funds tracked by Wall St. Rank held Immunome as of Q3 2022.

Based on Titleist Capital's 13F filing for Q3 2022, filed 14 Nov 2022.